Organization
Janssen Research and Development, LLC, Spring House, United States of america
3 abstracts
Abstract
ASSOCIATIONS OF BASELINE CLINICAL AND BIOMARKER FACTORS WITH SYMPTOMS AND FUTURE DEVELOPMENT OF CLINICALLY-APPARENT RHEUMATOID ARTHRITIS IN AN ACPA POSITIVE COHORTOrg: CU Anschutz Medical Campus, Aurora, United States of America, Janssen Research and Development, LLC, Spring House, United States of america, Benaroya Research Institute at Virginia Mason, Seattle, United States of America, University of California San Diego, La Jolla, United States of America, Stanford University, Stanford, United States of America,
Abstract
ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALOrg: Oregon Health and Science U, Portland, United States of america, Guy’s and St. Thomas NHS Foundation Trust, London, United Kingdom, Memorial University of Newfoundland, St. John’s, Canada, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Icahn School of Medicine at Mt Sinai, Dermatology, New York, United States of america,
Abstract
BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Janssen Research and Development, LLC, Spring House, United States of america, AMPEL BioSolutions, LLC, Charlottesville, United States of America, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, University of California, Los Angeles, Los Angeles, United States of America, Beth Isreal Deaconess Medical Center, Harvard Medical School, Boston, United States of America,